Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FlexStar is a multi-ingredient dietary supplement and nutraceutical primarily indicated for the support of joint health and the management of symptoms associated with degenerative joint conditions such as osteoarthritis. The formulation typically combines glucosamine sulfate, chondroitin sulfate, and methylsulfonylmethane (MSM). Glucosamine serves as a biochemical precursor for glycosaminoglycans and proteoglycans, which are essential structural components of the articular cartilage matrix. Chondroitin sulfate contributes to the cartilage's structural integrity and resistance to compression by promoting water retention and inhibiting degradative enzymes. MSM provides organic sulfur, which is necessary for the stabilization of connective tissues and may exert mild anti-inflammatory effects. Together, these components aim to alleviate joint pain, improve functional mobility, and potentially support the maintenance of healthy cartilage in patients with joint discomfort.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on FlexStar.